MyFinsight
Home
Blog
About
Contact
Download
Download image
Change in fair value of
convertible preferred stock...
$8.928M
Interest income
$3.323M
Net loss
-$68.87M
Total other income,
net
$12.201M
License revenue
$13M
Other expense, net
$0.05M
Loss from operations
-$81.071M
Total revenue
$13M
Total operating
expenses
$94.071M
Research and development
$74.042M
General and
administrative
$20.029M
Back
Back
Income Statement
source: myfinsight.com
Evommune, Inc. (EVMN)
Evommune, Inc. (EVMN)